Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Translational Oncology|April 15, 2014
Monitoring of tumor response to Cisplatin using optical spectroscopyJarich W Spliethoff, Daniel J Evers, Janneke E Jaspers, et al.
Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.
Mbio|May 15, 2024
TurboID mapping reveals the exportome of secreted intrinsically disordered proteins in the transforming parasite <i>Theileria annulata</i>Francis Brühlmann, Carmen Perry, Charlotte Griessen, et al.
Veterinary and Comparative Oncology|December 30, 2022
Organoids of patient-derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogsStephanie Scheemaeker, Marine Inglebert, Sylvie Daminet, et al.
The AAPS Journal|November 26, 2015
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast CancerHuixin Yu, Jeroen J M A Hendrikx, Sven Rottenberg, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
Cancer Research|August 6, 2009
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancerMarina Pajic, Jayasree K Iyer, Ariena Kersbergen, et al.
Cancer Research|December 17, 2014
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistanceJanneke E Jaspers, Wendy Sol, Ariena Kersbergen, et al.
Molecular Oncology|April 25, 2018
Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agentsNora M Gerhards, Vincent A Blomen, Merve Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in MiceMarina Pajic, Sohvi Blatter, Charlotte Guyader, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Translational Oncology|April 15, 2014
Monitoring of tumor response to Cisplatin using optical spectroscopyJarich W Spliethoff, Daniel J Evers, Janneke E Jaspers, et al.
Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.
Mbio|May 15, 2024
TurboID mapping reveals the exportome of secreted intrinsically disordered proteins in the transforming parasite <i>Theileria annulata</i>Francis Brühlmann, Carmen Perry, Charlotte Griessen, et al.
Veterinary and Comparative Oncology|December 30, 2022
Organoids of patient-derived medullary thyroid carcinoma: The first milestone towards a new in vitro model in dogsStephanie Scheemaeker, Marine Inglebert, Sylvie Daminet, et al.
The AAPS Journal|November 26, 2015
Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast CancerHuixin Yu, Jeroen J M A Hendrikx, Sven Rottenberg, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
Cancer Research|August 6, 2009
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancerMarina Pajic, Jayasree K Iyer, Ariena Kersbergen, et al.
Cancer Research|December 17, 2014
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistanceJanneke E Jaspers, Wendy Sol, Ariena Kersbergen, et al.
Molecular Oncology|April 25, 2018
Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agentsNora M Gerhards, Vincent A Blomen, Merve Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in MiceMarina Pajic, Sohvi Blatter, Charlotte Guyader, et al.
Pageof 13